Date: 2014-06-12
Type of information: Licensing agreement
Compound: SNG001
Company: AstraZeneca (UK) Synairgen (UK)
Therapeutic area: Infectious diseases - Respiratory diseases - Allergic diseases
Type agreement: licensing
Action mechanism: SNG001 is an inhaled interferon beta. It has a broad spectrum anti-viral effect and acts by delivering IFN-beta to the lungs when an infection, such as a common cold, begins to develop in the upper airways. Inhaled IFN-beta boosts the anti-viral defence and combats the spread of the virus, preventing or reducing the severity of exacerbations.
Disease: respiratory tract viral infections in patients with severe asthma
Details: * On June 12, 2014, AstraZeneca announced a global licence agreement with Synairgen, an AIM-listed UK company specialising in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. In early 2015, AstraZeneca will commence a Phase IIa study in patients with severe asthma, building on available clinical data from an initial Phase lla trial in a broad asthma population. SNG001 also provides the opportunity to expand the clinical programme in other pulmonary diseases including chronic obstructive pulmonary disease (COPD).
Financial terms: Under the terms of the exclusive licence agreement, AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and commercial milestones of up to $225 million. In addition, AstraZeneca will pay tiered royalties ranging from single-digit up to mid-teens on commercial sales. AstraZeneca will be responsible for future development costs.
Latest news:
